Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

Dolores Isla,1 Javier De Castro,2 Oscar Juan,3 Santiago Grau,4 Javier Orofino,5 Rocío Gordo,5 Carlos Rubio-Terrés,6 Darío Rubio-Rodríguez6 1Medical Oncology Department, Clinical Universitary Hospital Lozano Blesa, Zaragoza, 2Medical Oncology Department, Un...

Full description

Bibliographic Details
Main Authors:	Isla D, De Castro J, Juan O, Grau S, Orofino J, Gordo R, Rubio-Terrés C, Rubio-Rodríguez D
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-12-01
Series:	ClinicoEconomics and Outcomes Research
Subjects:	adverse event afatinib cost-analysis erlotinib non-small-cell lung cancer.
Online Access:	https://www.dovepress.com/costs-of-adverse-events-associated-with-erlotinib-or-afatinib-in-first-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/costs-of-adverse-events-associated-with-erlotinib-or-afatinib-in-first-peer-reviewed-article-CEOR

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

Internet

Similar Items